DK2349295T3 - Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer - Google Patents
Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer Download PDFInfo
- Publication number
- DK2349295T3 DK2349295T3 DK09826377.5T DK09826377T DK2349295T3 DK 2349295 T3 DK2349295 T3 DK 2349295T3 DK 09826377 T DK09826377 T DK 09826377T DK 2349295 T3 DK2349295 T3 DK 2349295T3
- Authority
- DK
- Denmark
- Prior art keywords
- strains
- ncimb
- pharmaceutical composition
- strain
- staphylococcus
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims description 53
- 229940039696 lactobacillus Drugs 0.000 title claims description 21
- 241000194017 Streptococcus Species 0.000 title claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims 16
- 208000015181 infectious disease Diseases 0.000 claims description 54
- 241000191940 Staphylococcus Species 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 25
- 238000011321 prophylaxis Methods 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 19
- 241001465754 Metazoa Species 0.000 claims description 17
- 241000191967 Staphylococcus aureus Species 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 9
- 206010040070 Septic Shock Diseases 0.000 claims description 9
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 8
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 8
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 8
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 8
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010000269 abscess Diseases 0.000 claims description 6
- 206010007247 Carbuncle Diseases 0.000 claims description 5
- 206010017553 Furuncle Diseases 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 5
- 208000021326 Ritter disease Diseases 0.000 claims description 5
- 206010041929 Staphylococcal scalded skin syndrome Diseases 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 241001147691 Staphylococcus saprophyticus Species 0.000 claims description 5
- 241000194025 Streptococcus oralis Species 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010014665 endocarditis Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 206010021531 Impetigo Diseases 0.000 claims description 4
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 206010031252 Osteomyelitis Diseases 0.000 claims description 4
- 241001134658 Streptococcus mitis Species 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 230000001332 colony forming effect Effects 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 206010040872 skin infection Diseases 0.000 claims description 4
- 206010007882 Cellulitis Diseases 0.000 claims description 3
- 206010016936 Folliculitis Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000013223 septicemia Diseases 0.000 claims description 3
- 235000014347 soups Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 235000014048 cultured milk product Nutrition 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000012053 oil suspension Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 235000020167 acidified milk Nutrition 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 39
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 39
- 239000000825 pharmaceutical preparation Substances 0.000 description 24
- 241000295644 Staphylococcaceae Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229930182555 Penicillin Natural products 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 6
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229960003085 meticillin Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 5
- 108010087702 Penicillinase Proteins 0.000 description 4
- 244000057717 Streptococcus lactis Species 0.000 description 4
- 235000014897 Streptococcus lactis Nutrition 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229950009506 penicillinase Drugs 0.000 description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229960003165 vancomycin Drugs 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 206010033078 Otitis media Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 208000005923 otitis media with effusion Diseases 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000024036 serous otitis media Diseases 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010053950 Teicoplanin Proteins 0.000 description 2
- 206010044013 Tonsillitis streptococcal Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 2
- 229940047766 co-trimoxazole Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 229960004273 floxacillin Drugs 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960001608 teicoplanin Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KOFBVFFPLADGGO-DUSUDKPKSA-N (3r,4s,5r,6r)-6-[(1r,2r)-1-amino-2-hydroxypropyl]oxane-2,3,4,5-tetrol Chemical compound C[C@@H](O)[C@@H](N)[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O KOFBVFFPLADGGO-DUSUDKPKSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014684 Endocarditis staphylococcal Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 206010017916 Gastroenteritis staphylococcal Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000008582 Staphylococcal Food Poisoning Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 229940040977 beta-lactamase resistant penicillins Drugs 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000008025 hordeolum Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940004311 lactobacillus casei rhamnosus Drugs 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 201000002190 staphyloenterotoxemia Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000037948 vancomycin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
1. Farmaceutisk præparat til profylakse mod og behandling af Staphylococcus-induce-rede infektioner eller tilstande i mennesker og dyr, hvor det omfatter en kombination af a) én eller flere levedygtige α-Streptococcus-stammer, som er valgt fra gruppen bestående af Streptococcus sanguis Il-stammerne med deponeringsnumrene NCIMB 40104, NCIMB 40105, NCIMB 40106 og NCIMB 40873, Streptococcus mitis-stammerne med deponeringsnumrene NCIMB 40107 og NCIMB 40874, Streptococcus oralis-stammerne med deponeringsnumrene NCIMB 40875 og NCIMB 40876, Streptococcus lactis-stammen L1A med deponeringsnummeret NCIMB 40157; og b) én eller flere levedygtige Lactobacillus-stammer, som er valgt fra gruppen bestående af Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564, Lactobacillus plantarum-stammen LB3 med deponeringsnummeret DSM 17852, Lactobacillus plantarum-stammen LB7 med deponeringsnummeret DSM 17853, Lactobacillus plantarum-stammen LB931 med deponeringsnummeret DSM 11918 og Lactobacillus fermentum-stammen LB Ess-1 med deponeringsnummeret DSM 17851; i mindst ét farmaceutisk acceptabelt medium, i hvilket stammerne bevarer deres levedygtighed.
2. Farmaceutisk præparat ifølge krav 1, hvor det omfatter en kombination afa) Streptococcus sanguis-stammerne med deponeringsnumrene NCIMB 40104 og NCIMB 40106 og Streptococcus oralis-stammen med deponeringsnummeret NCIMB 40876, og b) Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564.
3. Farmaceutisk præparat ifølge krav 2, hvor det omfatter en kombination af Streptococcus sanguis Il-stammen med deponeringsnummeret NCIMB 40104 og Lactobacillus rhamnosus-stammen LB21 med deponeringsnummeret NCIMB 40564.
4. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor den ene eller de flere Streptococcus-stammer er til stede i en samlet mængde på 104-1011, fortrinsvis 105-1010, mest fortrinsvis 106-109, kolonidannende enheder pr. ml af det brugsklare præparat, og hvor den ene eller de flere Lactobacillus-stammer er til stede i en mængde på 104-1011, fortrinsvis 105-1010, mest fortrinsvis 106-109, kolonidannende enheder pr. ml af det brugsklare præparat.
5. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det er en oral, oromucosal, gingival, nasal, dental, kutan/hud, vaginal, rektal eller øreformule-ring.
6. Farmaceutisk præparat ifølge krav 5, hvor det hårform af et pulver, et granulat, en ’’cachet”, en kapsel, en tablet, en pasta, en creme, en gel, en sårsalve, en salve, en skum, en pasta, en lotion, en creme, en oliesuspension, en spray, en suspension, en opløsning, en emulsion, et plaster, en stav, en spray, fortrinsvis en nasal spray, eller en buccal spray, et mundskyllemiddel eller en drik eller opløsning.
7. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det farmaceutisk acceptable medium er et syrnet eller fermenteret mælkeprodukt, fortrinsvis syrnet mælk, yoghurt og mælk eller frugtjuice, iscreme, suppe og frugtdrikke.
8. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor det farmaceutisk acceptable medium er et dyrefoder, fortrinsvis valle, tørfoder eller en koncentreret suspension, når præparatet ifølge opfindelsen administreres til dyr.
9. Farmaceutisk præparat ifølge et hvilket som helst af de foregående krav, hvor stammerne deri er lyofiliserede.
10. Farmaceutisk præparat ifølge krav 9, hvor det er til stede i en NaCI-opløsning, en glukoseopløsning eller skummetmælk.
11. Kit til profylakse mod og behandling af Staphylococcus-inducerede infektioner eller tilstande, hvor det omfatter to eller flere separate formuleringer, som er beregnet til at blive administreret samtidigt eller i rækkefølge inden for en forudbestemt tidsperiode, fortrinsvis inden for 24 timer, til et menneske eller et dyr, som har behov derfor, hvor kittet omfatter en kombination af stammer ifølge krav 1a) og stammer ifølge krav 1b), hvor hver formulering i kittet omfatter mindst én stamme ifølge krav 1a) og/eller mindst én stamme ifølge krav 1 b).
12. Farmaceutisk præparat ifølge et hvilket som helst af kravene 1-10 eller kit ifølge krav 11 til anvendelse i en fremgangsmåde til profylakse mod og/eller behandling af en Staphylococcus-induceret infektion eller tilstand.
13. Farmaceutisk præparat eller kit til anvendelse ifølge krav 12, hvor den Staphylo-coccus-inducerede infektion eller tilstand er induceret af Staphylococcus aureus-, Staphylococcus epidermidis- og/eller Staphylococcus saprophyticus-stammer, især multiresistente Staphylococcus aureus-(MRSA)-stammer.
14. Farmaceutisk præparat eller kit til anvendelse ifølge krav 13, hvor den Staphylo-coccus-inducerede infektion eller tilstand er til stede i mundhulen, i øret, i den nasale og/eller faryngale region, i mave/tarmkanalen, på huden eller andre steder eller organer i kroppen.
15. Farmaceutisk præparat eller kit til anvendelse ifølge krav 12, hvor den Staphylo-coccus-inducerede infektion eller tilstand er mindre hudinfektioner, fortrinsvis bumser, impetigo, bylder, cellulitis folliculitis, furunkler, karbunkler, skoldet hudsyndrom og abscesser, samt livstruende sygdomme, fortrinsvis lungebetændelse, meningitis, osteomyelitis, endocarditis, toksisk shocksyndrom (TSS) og septikæmi.
16. Anvendelse af et farmaceutisk præparat ifølge et hvilket som helst af kravene 1-10 eller kit ifølge krav 11 til fremstilling af et lægemiddel til profylakse mod og/eller behandling af Staphylococcus-inducerede infektioner eller tilstande i mennesker og dyr.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11528308P | 2008-11-17 | 2008-11-17 | |
| SE0850079 | 2008-11-17 | ||
| PCT/SE2009/051300 WO2010056198A1 (en) | 2008-11-17 | 2009-11-17 | Pharmaceutical preparation comprising a combination of streptococcus strains and lactobacillus strains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2349295T3 true DK2349295T3 (da) | 2017-01-23 |
Family
ID=42170160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09826377.5T DK2349295T3 (da) | 2008-11-17 | 2009-11-17 | Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110256179A1 (da) |
| EP (1) | EP2349295B8 (da) |
| CN (1) | CN102215849A (da) |
| AU (1) | AU2009314666B2 (da) |
| CA (1) | CA2742727A1 (da) |
| DK (1) | DK2349295T3 (da) |
| IL (1) | IL212698A (da) |
| PL (1) | PL2349295T3 (da) |
| RU (1) | RU2011124506A (da) |
| WO (1) | WO2010056198A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206599D0 (en) | 2012-04-13 | 2012-05-30 | Univ Manchester | Probiotic bacteria |
| US8927242B2 (en) * | 2012-05-10 | 2015-01-06 | Nubiome, Inc. | Treatment and prophylaxis for obsessive compulsive disorder |
| FR2999601B1 (fr) * | 2012-12-17 | 2015-01-30 | Urgo Lab | Methode pour prevenir et/ou traiter les infections, colonisations ou maladies liees a staphylococcus aureus, pseudomonas aeruginosa, streptococcus pyogenes, enterococcus faecium, enterobacter cloacae, proteus mirabilis et/ou bacteroides fragilis |
| WO2015140299A1 (en) * | 2014-03-20 | 2015-09-24 | Universiteit Antwerpen | Oronasopharyngeal probiotics |
| HUE047234T2 (hu) * | 2014-10-28 | 2020-04-28 | Dmg Italia Srl | Szimetikon-tartalmú biológiai gát orr-garati vezeték fertõzései kezelésében történõ alkalmazásra |
| US11406671B2 (en) | 2015-04-24 | 2022-08-09 | The Translational Genomics Research Institute | Compositions and methods for augmenting the nasal microbiome |
| WO2020001747A1 (en) | 2018-06-26 | 2020-01-02 | Symrise Ag | Lactobacillus plantarum for skin care |
| EP3849574A1 (en) | 2018-09-10 | 2021-07-21 | Lactobio A/S | Method for reducing the transfer of pathogenic microorganisms |
| KR102167387B1 (ko) * | 2020-05-14 | 2020-10-19 | 코스맥스 주식회사 | 피부 장벽 강화, 피부 보습 또는 항노화를 위한 조성물 |
| CN113462616A (zh) * | 2021-08-19 | 2021-10-01 | 上海昊岳食品科技有限公司 | 一株人源鼠李糖乳杆菌glr8及其制备方法 |
| CN119464165A (zh) * | 2025-01-16 | 2025-02-18 | 中日友好医院(中日友好临床医学研究所) | 口腔链球菌zrsor-5及其相关产品、方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE461310B (sv) | 1988-07-12 | 1990-01-29 | Ellemtel Utvecklings Ab | Saett och anordning foer att i en digital tidsvaeljare genomkoppla en bredbandsfoerbindelse |
| SE463349B (sv) | 1989-02-15 | 1990-11-12 | Grahn Eva E | Farmaceutiskt preparat foer profylax mot och/eller behandling av beta-streptokockinducerad tonsillit |
| SE465206B (sv) * | 1989-12-22 | 1991-08-12 | Eva Grahn | Farmaceutisk beredning foer bekaempning av patogena tarmbakterier |
| SE511524C2 (sv) * | 1997-06-02 | 1999-10-11 | Essum Ab | Lactobacillus casei rhamnosus-stam samt farmaceutisk beredning för bekämpning av patogena tarmbakterier |
| RO112995B1 (ro) * | 1997-08-05 | 1998-03-30 | Rodica Teodorescu | Produs medicamentos pentru terapia colonului |
| SE519648C2 (sv) * | 1998-03-06 | 2003-03-25 | Essum Ab | Ny stam av Lactobacillus plantarum |
| SE511648C2 (sv) | 1998-04-17 | 1999-11-01 | Bacterum Ab | Streptokockpreparat för behandling av öroninflammation |
| NZ512275A (en) * | 1998-12-11 | 2003-11-28 | Urex Biotech Inc | Probiotic therapy delivered to women by oral administration of selected lactobascilli that have antagonistic properties against urogenital pathogens |
| TW588109B (en) * | 2000-07-29 | 2004-05-21 | Tcell Biotechnology Food Co Lt | Lactobacillus rhamnosus strain and uses thereof |
| US20030175305A1 (en) * | 2002-01-08 | 2003-09-18 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
| US20060258596A1 (en) * | 2003-02-14 | 2006-11-16 | Walsh Timothy R | Antimicrobial agents |
| EP1481681A1 (en) * | 2003-05-30 | 2004-12-01 | Claudio De Simone | Lactic acid bacteria combination and compositions thereof |
| ITMI20042189A1 (it) | 2004-11-16 | 2005-02-16 | Anidral Srl | Composizione a base di batteri probiotici e suo uso nella prevenzione e-o nel trattamento di patologie e-o infezioni respiratorie e nel miglioramento della funzionalita' intestinale |
| WO2007108763A1 (en) * | 2006-03-17 | 2007-09-27 | Probac Ab | Use of lactobacillus strains for promoting immunotolerance in autoimmune disease |
-
2009
- 2009-11-17 DK DK09826377.5T patent/DK2349295T3/da active
- 2009-11-17 US US12/998,615 patent/US20110256179A1/en not_active Abandoned
- 2009-11-17 PL PL09826377T patent/PL2349295T3/pl unknown
- 2009-11-17 CN CN2009801457628A patent/CN102215849A/zh active Pending
- 2009-11-17 CA CA2742727A patent/CA2742727A1/en not_active Abandoned
- 2009-11-17 EP EP09826377.5A patent/EP2349295B8/en active Active
- 2009-11-17 WO PCT/SE2009/051300 patent/WO2010056198A1/en active Application Filing
- 2009-11-17 AU AU2009314666A patent/AU2009314666B2/en active Active
- 2009-11-17 RU RU2011124506/10A patent/RU2011124506A/ru unknown
-
2011
- 2011-05-05 IL IL212698A patent/IL212698A/en active IP Right Grant
-
2015
- 2015-10-08 US US14/878,743 patent/US10596244B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011124506A (ru) | 2012-12-27 |
| IL212698A0 (en) | 2011-07-31 |
| PL2349295T3 (pl) | 2017-06-30 |
| US10596244B2 (en) | 2020-03-24 |
| WO2010056198A1 (en) | 2010-05-20 |
| CN102215849A (zh) | 2011-10-12 |
| CA2742727A1 (en) | 2010-05-20 |
| AU2009314666B2 (en) | 2015-01-29 |
| EP2349295B1 (en) | 2016-10-26 |
| US20110256179A1 (en) | 2011-10-20 |
| EP2349295A4 (en) | 2012-12-12 |
| AU2009314666A1 (en) | 2010-05-20 |
| EP2349295A1 (en) | 2011-08-03 |
| IL212698A (en) | 2013-12-31 |
| EP2349295B8 (en) | 2016-12-14 |
| US20160089428A1 (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2349295T3 (da) | Farmaceutisk præparat omfattende en kombination af Streptococcus-stammer og Lactobacillus-stammer | |
| ES2245801T3 (es) | Preparacion farmaceutica que comprende lactobacillus casei rhamnosus. | |
| US20020022019A1 (en) | Method of reducing ecologically adverse changes of the gastro intestinal microbial flora in patients under treatment with medicaments | |
| EP1162987B1 (en) | Pharmaceutical composition for medical and veterinary use for regenerating intestinal flora in diarrhoea or dyspeptic syndrome | |
| US12128077B2 (en) | Strains, composition and method of use | |
| JP2001258549A (ja) | ヘリコバクターピロリに対して抗菌活性を有するラクトバシルスアシドフィルスｈｙ２１７７、ラクトバシルスカセイｈｙ２７４３及びそれらを用いた乳酸菌製剤と発酵乳 | |
| ES2331650T3 (es) | Utilizacion de bacterias probioticas en el tratamiento de una infeccion. | |
| WO2019212379A1 (ru) | Пищевая, косметическая и фармацевтическая композиция с иммуномодулирующим и протективным антивирусным эффектом | |
| Nhu et al. | The relationship between the microbiome and antimicrobial resistance | |
| ES2373411T3 (es) | Inhibición del crecimiento y eliminación del staphylococcus aureus resistente a la meticilina por bacterias ácido lácticas. | |
| WO2017105267A1 (en) | New probiotic starter culture for human and animal use | |
| JP2001002578A (ja) | Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ除菌性医薬品 | |
| Cresci | Clinical research: The use of probiotics with the treatment of diarrhea | |
| KR100409940B1 (ko) | 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품 | |
| Cazzato et al. | Role of probiotics in Helicobacter pylori infections | |
| KR100437487B1 (ko) | 헬리코박터 필로리의 생육을 특이적으로 억제하는 유산균,그 이용방법 및 그를 함유한 제품 | |
| Sharma et al. | AN OVERVIEW: PROBIOTIC MICROBES | |
| Kroeker et al. | Treatment of Ulcerative Colitis | |
| Olmstead et al. | Probiotics and Antibiotic-Associated Diarrhea | |
| Kaul et al. | Probiotics: stepping stene towards a healthy life |